Cite
APA Citation
Arciero, V., Luo, J., Parmar, A., Dai, W. F., Beca, J. M., Raphael, M. J., Isaranuwatchai, W., Habbous, S., Tadrous, M., Earle, C. C., Biagi, J. J., Mittmann, N., Arias, J., Gavura, S., & Chan, K. K. W. (2022). real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer. JNCI cancer spectrum, 6(4), . http://access.bl.uk/ark:/81055/vdc_100158014534.0x00000a